Jelena M Milenkovic

Prof. Dr. Jelena M Milenkovic

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2017 in Biomedical Papers
Verified
Journal Article
Open access
PDF file
Jelena M MilenkovicJelena M Milenkovic
Jelena M Milenkovic
MMMaja Milojkovic
Maja Milojkovic
TSTatjana Jevtovic Stoimenov
Tatjana Jevtovic Stoimenov
BDBoris Djindjic
Boris Djindjic
EMEdita Miljkovic
Edita Miljkovic
Plasminogen activator inhibitor type 1 (PAI-1) is the main physiologic inhibitor of fibrinolysis. However, it is also involved in many physiological processes such as extracellular matrix (ECM) proteolysis and remodeling, cell adhesion, motility, and apoptosis, angiogenesis, etc. The aim of the study was to summarize current knowledge and gain insights into the mechanisms of PAI-1 action in the processes of stromal remodeling and diseases with considerable matrix pathologies (atherosclerosis, tissue fibrosis, cancer metastasis, pregnancy related complications, etc). As a component of an early cellular response to injury, PAI-1 reacts with membrane surface proteins and participates in the initiation of intracellular signaling, specifically cytoskeletal reorganization and motility. Complexity of ECM homeostasis resides in varying relation of the plasminogen system components and other matrix constituents. Inflammatory mediators (transforming growth factor-β and interferon-γ) and hormones (angiotensin II) are in the close interdependent relation with PAI-1. Also, special attention is devoted to the role of increased PAI-1 concentrations due to the common 4G/5G polymorphism. Some of the novel mechanisms of ECM modification consider PAI-1 dependent stabilization of urokinase mediated cell adhesion, control of the vascular endothelial cadherin trafficking and interaction with endothelial cells proteasome, its relation to matrix metalloproteinase 2 and osteopontin, and oxidative inhibition by myeloperoxidase. Targeting and/or alteration of PAI-1 functions might bring benefit to the future therapeutic approaches in diseases where ECM undergoes substantial remodeling.

1 July 2016 in Pediatric Rheumatology
Verified
Journal Article
Open access
PDF file
Jelena M MilenkovicJelena M Milenkovic
Jelena M Milenkovic
JVJelena Vojinovic
Jelena Vojinovic
MDMaruša Debeljak
Maruša Debeljak
NTNataša Toplak
Nataša Toplak
DLDragana Lazarević
Dragana Lazarević
Andrej VeljkovicAndrej Veljkovic
Andrej Veljkovic
The Mediterranean fever (MEFV) gene codes for protein pyrin, one of the regulators of inflammasome activity in innate immune cells. Mutations in this gene are considered the primary cause of Familial Mediterranean fever, but are also found in other monogenic and multifactorial autoinflammatory diseases. The aim of the study was to determine if healthy carriers of MEFV gene mutations and R202Q polymorphism have clinical manifestations of inflammation and impaired oxidative stress parameters. One hundred DNA samples from healthy volunteers (13.3 ± 8.87 years of age (mean ± SD); range 2–35) were sequenced by ABI PRISM 310 automated sequencer (PE Applied Biosystems, Norwalk, USA). The Eurofever questionnaire was used to collect retrospectively medical history data. Oxidative stress was determined by measuring spectrophotometrically thiobarbituric acid reactive substances (TBARS) in plasma and erythrocytes, as well as advanced oxidation protein products in plasma. Superoxide dismutase (SOD) activity was determined by McCord and Fridovich method in plasma and erythrocytes, while the catalase erythrocyte activity was assessed using a catalase ELISA kit. We found heterozygous carriers of K695R/N mutations in 5 %, E148Q/N mutations in 6 %, R202Q homozygous polymorphism in 10 % and heterozygous R202Q alterations in 45 % of healthy volunteers. The MEFV mutation carriers and R202Q polymorphism homozygotes reported significantly more often recurrent febrile episodes (p = 0.009), diffuse abdominal pain (p = 0.025), and malaise (p = 0.012) compared to non-carriers. Erythrocyte TBARS levels and plasma SOD activity were higher in persons with MEFV mutations and R202Q/R202Q (p = 0.03 and p = 0.049, respectively). Healthy individuals may bear E148Q and K695R MEFV gene mutations, as well as R202Q polymorphism in homozygous state. The determined gene alterations contribute to a subtle oxidative stress and may be associated with more frequent episodes of fever and unspecific inflammatory manifestations. An incomplete penetrance or variable expressivity of R202Q in populations of different ethnicity could influence the expression of autoinflammatory diseases phenotype.

12 June 2023 in Cells
Verified
Journal Article
Open access
PDF file
DSDijana Stojanović
Dijana Stojanović
MSMiodrag Stojanovic
Miodrag Stojanovic
Jelena M MilenkovicJelena M Milenkovic
Jelena M Milenkovic
AVAleksandra Veličkov
Aleksandra Veličkov
Aleksandra IgnjatovicAleksandra Ignjatovic
Aleksandra Ignjatovic
MMMaja Milojkovic
Maja Milojkovic
The cellular mechanisms and signaling network that guide the cardiac disease pathophysiology are inextricably intertwined, which explains the current scarcity of effective therapy and to date remains the greatest challenge in state-of-the-art cardiovascular medicine. Accordingly, a novel concept has emerged in which cardiomyocytes are the centerpiece of therapeutic targeting, with dysregulated mitochondria as a critical point of intervention. Mitochondrial dysfunction pluralism seeks a multi-faceted molecule, such as renalase, to simultaneously combat the pathophysiologic heterogeneity of mitochondria-induced cardiomyocyte injury. This review provides some original perspectives and, for the first time, discusses the functionality spectrum of renalase for mitochondrial dysfunction improvement within cardiac disease, including its ability to preserve mitochondrial integrity and dynamics by suppressing mitochondrial ΔΨm collapse; overall ATP content amelioration; a rise of mtDNA copy numbers; upregulation of mitochondrial genes involved in oxidative phosphorylation and cellular vitality promotion; mitochondrial fission inhibition; NAD+ supplementation; sirtuin upregulation; and anti-oxidant, anti-apoptotic, and anti-inflammatory traits. If verified that renalase, due to its multi-faceted nature, behaves like the “guardian of mitochondria” by thwarting pernicious mitochondrial dysfunction effects and exerting therapeutic potential to target mitochondrial abnormalities in failing hearts, it may provide large-scale benefits for cardiac disease patients, regardless of the underlying causes.

10 August 2022 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
Jelena M MilenkovicJelena M Milenkovic
Jelena M Milenkovic
BDBoris Djindjic
Boris Djindjic
BDBranka Djordjevic
Branka Djordjevic
Vladana StojiljkovicVladana Stojiljkovic
Vladana Stojiljkovic
DSDijana Stojanović
Dijana Stojanović
IMIvan Matejic
Ivan Matejic
Background: Coronavirus disease 2019 (COVID‐19) profoundly affects the immune and hematopoietic systems with various degrees of reactive changes in the blood cell counts. Immuno‐inflammatory indices are considered a simple and effective tool in the prediction of COVID‐19 outcomes. We aimed to evaluate and compare the usefulness of leukocyte and platelet counts‐based immuno‐inflammatory indices on admission to hospital in predicting COVID‐19 progression and mortality.Methods: A total of 945 patients were enrolled. In addition to blood cell counts, we assessed hemogram‐derived immuno‐inflammatory indices in relation to COVID‐19 progression and death. The indices were tested by analysis of variance, receiver operating characteristic curve analysis, and binomial logistic regressions.Results: Patients with severe COVID‐19 had significantly higher counts of neutrophils, eosinophils, and large immature cells (LIC), while decreased counts of platelets and monocytes. Lymphopenia was found in all of the patients, but without significant association with the outcomes. Patients with a LIC count ≥0.265 x 09/L had 54.7% more odds of having COVID‐19 progression. In multivariable analyses, platelets/neutrophil‐to‐lymphocyte ratio (P/NLR) and platelets‐to‐neutrophil radio (P/N) were significant independent predictors of COVID‐19 progression and mortality. The odds of a poor outcome were two times higher in cases with P/NLR < 43 x 109/L and P/N < 29 x 109/L.Conclusion: Indices that include platelet count in combination with neutrophil and/or lymphocyte counts displayed the best discriminatory ability and prognostic value of COVID‐19 outcomes. Additionally, LIC showed promising results in the early identification of severe COVID‐19.

13 May 2020 in Journal of Assisted Reproduction and Genetics
Verified
Journal Article
Closed access
PDF file
Jelena M MilenkovicJelena M Milenkovic
Jelena M Milenkovic
MMMaja Milojkovic
Maja Milojkovic
DMDejan Mitic
Dejan Mitic
TJTatjana Jevtović-Stoimenov
Tatjana Jevtović-Stoimenov
ZSZaklina Smelcerovic
Zaklina Smelcerovic
NBNovica Bojanic
Novica Bojanic

29 April 2019 in Ginekologia Polska
Verified
Journal Article
Open access
PDF file
DMDejan Mitic
Dejan Mitic
Jelena M MilenkovicJelena M Milenkovic
Jelena M Milenkovic
MMMaja Milojkovic
Maja Milojkovic
MJMiljan Jeremic
Miljan Jeremic
APAleksandra Petric
Aleksandra Petric
MBMarin Basic
Marin Basic
Objectives: Embryo implantation represents the major limiting step during in vitro fertilization (IVF) procedure. Immu- nological and coagulation abnormalities were shown to have a substantial part in multifactorial etiology of IVF failure. We aimed to investigate the effect of short-term low-dose dexamethasone plus acetylsalicylic acid (ASA) treatment, starting at the time of embryo transfer, on the implantation and clinical pregnancy rates in general IVF population. Material and methods: Out of 233 consecutive patients undergoing fresh IVF/intracytoplasmic sperm injection (ICSI) cycles 64 received an adjuvant treatment consisting of dexamethasone (0.5 mg/day) plus ASA (100 mg/day) (DA group), starting on the day of embryo transfer. Patients not receiving these medications comprised a control group. Results: Significantly more patients in DA group had positive ß-hCG values than controls (59.38% vs. 37.67%, p = 0.004) (OR = 2.42, 95% CI: 1.33–4.41). Implantation rate was 26.53% in DA group and 15.92% in controls (p = 0.0294). Clinical preg- nancy rate per started cycle was higher in DA group (43.59%) than controls (28.92%), but the difference was not significant (p = 0.0879; OR = 1.99, 95% CI: 0.89–4.41). Conclusions: Our study shows a potential benefit of dexamethasone plus ASA adjuvant treatment in females undergoing IVF/ICSI procedure. As these results show improvement of IVF outcome, a greater number of patients undergoing this type and regime of adjuvant treatment should be investigated. Objectives: Embryo implantation represents the major limiting step during in vitro fertilization (IVF) procedure. Immu- nological and coagulation abnormalities were shown to have a substantial part in multifactorial etiology of IVF failure. We aimed to investigate the effect of short-term low-dose dexamethasone plus acetylsalicylic acid (ASA) treatment, starting at the time of embryo transfer, on the implantation and clinical pregnancy rates in general IVF population. Material and methods: Out of 233 consecutive patients undergoing fresh IVF/intracytoplasmic sperm injection (ICSI) cycles 64 received an adjuvant treatment consisting of dexamethasone (0.5 mg/day) plus ASA (100 mg/day) (DA group), starting on the day of embryo transfer. Patients not receiving these medications comprised a control group. Results: Significantly more patients in DA group had positive ß-hCG values than controls (59.38% vs. 37.67%, p = 0.004) (OR = 2.42, 95% CI: 1.33–4.41). Implantation rate was 26.53% in DA group and 15.92% in controls (p = 0.0294). Clinical preg- nancy rate per started cycle was higher in DA group (43.59%) than controls (28.92%), but the difference was not significant (p = 0.0879; OR = 1.99, 95% CI: 0.89–4.41). Conclusions: Our study shows a potential benefit of dexamethasone plus ASA adjuvant treatment in females undergoing IVF/ICSI procedure. As these results show improvement of IVF outcome, a greater number of patients undergoing this type and regime of adjuvant treatment should be investigated.